{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:20:28Z","timestamp":1788373228079,"version":"build-2803163510"},"reference-count":12,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R42CA141907"],"award-info":[{"award-number":["R42CA141907"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background and objective<\/jats:title><jats:p>Intratumoral administration of chemotherapeutic agents is a treatment modality that has proven efficacious in reducing the recurrence of tumours and increases specificity of treatment while minimizing systemic side effects. Direct intratumoral injection of malignant airway obstruction has potential therapeutic benefits but tissue drug concentrations and side\u2010effect profiles are poorly understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Bronchial wall injection of generic paclitaxel (PTX) (102 injections of 0.05, 0.5, 1.5 or 2.5 mg\/mL in 10 healthy pigs), saline (14 injections in 2 healthy pigs) or Abraxane (ABX) (24 injections of 0.5 mg\/mL in 4 healthy pigs) was performed with a microneedle infusion catheter. Local histopathology, plasma and tissue PTX concentrations were evaluated at 7, 20 or 28 days post\u2010injection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Injection of generic PTX directly into the bronchial wall at doses up to 1.5 mg\/mL only caused minimal tissue injury. Dose\u2010limiting tissue reaction was observed at 2.5 mg\/mL. Plasma PTX was detectable for up to 5 days but not at 28 days, with area under the curve (AUC)<jats:sub>(0\u20105d)<\/jats:sub> 20\u2010 to 50\u2010fold lower than the AUC<jats:sub>(0\u2010\u221e)<\/jats:sub> of 6300 ng h\/mL for the approved intravenous dose. At 7 and 28 days post\u2010injection, bronchial PTX tissue concentrations were above a 10\u2010nmol\/L cancer therapeutic level. PTX was not found in peripheral tissues. Similar results were observed between ABX and generic PTX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Results of these studies confirm the administration of PTX directly into the bronchial wall is safe and feasible. PTX was detectable in plasma for &lt;7 days but tissue concentrations remained therapeutic throughout the follow\u2010up period.<\/jats:p><\/jats:sec>","DOI":"10.1111\/resp.13214","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T01:42:41Z","timestamp":1510710161000},"page":"399-405","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetics and safety of paclitaxel delivery into porcine airway walls by a new endobronchial drug delivery catheter"],"prefix":"10.1111","volume":"23","author":[{"given":"Hisashi","family":"Tsukada","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery Brigham and Women's Hospital  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plamena","family":"Entcheva\u2010Dimitrov","sequence":"additional","affiliation":[{"name":"Mercator MedSystems  Emeryville CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Ernst","sequence":"additional","affiliation":[{"name":"Steward Medical Group  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaan","family":"Rafeq","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Steward St. Elizabeth's Medical Center  Brighton MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Keating","sequence":"additional","affiliation":[{"name":"CBSET  Lexington MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk P.","family":"Seward","sequence":"additional","affiliation":[{"name":"Mercator MedSystems  Emeryville CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2991-7758","authenticated-orcid":false,"given":"Lonny","family":"Yarmus","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, Section of Interventional Pulmonology Johns Hopkins University  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Program.Cancer Statistics. [Accessed 15 Sep 2016.] Available from URL:http:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.6.1803"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-013-0013-x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.24012"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2010.12.040"},{"key":"e_1_2_8_7_1","first-page":"4242","article-title":"Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local\u2010regional therapy of lung cancer tumor nodules in mice","volume":"5","author":"Harper E","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0345-5"},{"key":"e_1_2_8_9_1","first-page":"571","article-title":"Intratumoral chemotherapy for lung cancer: re\u2010challenge current targeted therapies","volume":"7","author":"Hohenforst\u2010Schmidt W","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.03.009"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/LBR.0000000000000209"},{"key":"e_1_2_8_12_1","unstructured":"Taxol (Paclitaxel) Injection Solution Package Insert. Revised: 01\/2008. Bristol\u2010Myers Squibb Company."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0334"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fresp.13214","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.13214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T14:40:14Z","timestamp":1695566414000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.13214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/resp.13214"],"URL":"https:\/\/doi.org\/10.1111\/resp.13214","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]}}}